Daily dosing prophylaxis for haemophilia: A randomized crossover pilot study evaluating feasibility and efficacy

Haemophilia

Volumn 18, Issue 6, 2012, Pages 855-859

  Lindvall, K ^a   Astermark, J ^a   Bjorkman S ^b   Ljung, R ^c   Carlsson, K S ^a   Persson, S ^a   Berntorp, E ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor VIII IX; Haemophilia; Prophylaxis; QoL

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG COST; FEASIBILITY STUDY; HEALTH CARE COST; HEMOPHILIA; HUMAN; PILOT STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; JOINT DISEASES; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; YOUNG ADULT;

EID: 84868206189     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02879.x     Document Type: Article

References (17)

1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
2. Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
3. van den Berg HM, Fischer K, van der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002;8 (Suppl. 2):43-6.
4. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
5. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
7. Gringeri A, Lundin B, S VONM, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
8. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
9. Steen Carlsson K, Höjgård S, Lindgren A et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26.
10. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
11. Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
12. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
13. Collins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
14. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
15. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
16. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
17. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.